 Biocept Inc NASDAQ: BIOC will collaborate with Protean BioDiagnostics Inc to research Biocepts Target Selector molecular assays ability to determine EGFR status in non-small cell lung cancer NSCLC patients. The research will be conducted in an independent pathology laboratory setting. 